**Trader consensus on no hantavirus vaccine approval or licensure in 2026 reflects the early-stage status of all candidates.** Multiple mRNA, DNA, and viral-vectored constructs targeting Andes or other strains remain in preclinical or initial Phase 1 testing, with no Phase 3 efficacy trials active or planned for completion this year. Recent promising single-dose mRNA results in hamster models and Korean government-backed sa-mRNA optimization projects have advanced basic research but have not produced clinical-grade material or human safety/immunogenicity data sufficient for regulatory review. Existing inactivated vaccines licensed only in parts of Asia target Old World hantaviruses and do not address New World strains or meet Western approval standards. Realistic shifts could occur only with an unforeseen major outbreak triggering emergency-use authorization or accelerated pathways, though current surveillance and model timelines make this improbable before December 2026.